Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Income from Continuing Operations data on record, last reported at 34431000.0 in Q4 2022.

  • For Q4 2022, Income from Continuing Operations fell 129.4% year-over-year to 34431000.0; the TTM value through Dec 2022 reached 115909000.0, down 195.64%, while the annual FY2025 figure was 158349000.0, 5.96% up from the prior year.
  • Income from Continuing Operations reached 34431000.0 in Q4 2022 per AVIR's latest filing, down from 8066000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 117132000.0 in Q4 2021 and bottomed at 42077000.0 in Q1 2022.
  • Average Income from Continuing Operations over 3 years is 472166.67, with a median of 9029500.0 recorded in 2020.
  • Peak YoY movement for Income from Continuing Operations: surged 870.14% in 2021, then tumbled 2136.06% in 2022.
  • A 3-year view of Income from Continuing Operations shows it stood at 20656000.0 in 2020, then soared by 467.06% to 117132000.0 in 2021, then plummeted by 129.4% to 34431000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 34431000.0 in Q4 2022, 8066000.0 in Q3 2022, and 31335000.0 in Q2 2022.